Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: May 13, 2020
Context: The filing serves as a Regulation FD disclosure to provide an update on the top-line results of the Company's HOPE-2 clinical trial. The update was delivered via a slide presentation attached as Exhibit 99.1.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly informational regarding clinical trial results.
Material Changes
The material event reported is the release of top-line results for the HOPE-2 clinical trial. No financial changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company provided an update on the HOPE-2 clinical trial results through a slide presentation available on its investor website and attached to this filing.
Legal Disclaimer: The information contained in this Form 8-K and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. It is not subject to the liabilities of that section and shall not be incorporated by reference into any Securities Act or Exchange Act filing unless expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached slide presentation (Exhibit 99.1) for specific details on the HOPE-2 clinical trial top-line results.
- Verify the presentation on the Company's official website under the "Investors" section at www.capricor.com.
- Note that this filing does not constitute a formal financial report or contain audited financial data.